Asia Pacific Hormone Refractory Breast Cancer Market Size, Share, Competitive Landscape and Trend Analysis Report by TREATMENT and by Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

Breast cancer is the most common type of malignant cancer prevalent in women above the age of 40. According to the estimates of World Health Organization, cancer is the most fatal human disease accounting for the deaths of ~8.2 million people worldwide in 2012. Among these deaths, breast cancer was found to be most prominent disease among women that killed ~521,000 individuals. Presently, increasing number of hormone therapies have made refractory breast cancers resistant toward therapeutics, termed as hormone-resistant breast cancers. However, recently developed hormone refractory breast cancer chemotherapeutic agents such as, trastuzumab and everolimus, alone or in combination, are under clinical trials for the effective treatment of hormone refractory breast cancers.

Key factors responsible for the growth of this market involve increasing incidences of breast cancers, aging population, demands of advanced therapeutics, increasing prevalence of hormone refractory breast cancers, and the presence of a significant number of anticancer pipeline drugs. Rising life span of cancer-affected population is one of the other factors responsible for the growth of this market. However, social stigma of testing breast cancer lacks technological reach. Insufficient advanced chemotherapeutic treatments restraining the hormone refractory breast cancer market. Substantial number of new chemical entities (NCEs) in various phases of clinical trials will emerge as potential opportunities in the Asia Pacific market.

The Asia Pacific hormone refractory breast cancer market is segmented into China, Japan, India, Australia and others. The Asia-Pacific region is expected to rise at the significant pace, owing to rapid growth of pharmaceutical and healthcare industry along with the improved purchasing power of the service providers in this region. Rapidly emerging economies and the rise of medical tourism in regions such as India and China, will drive the growth of hormone refractory breast cancer market. Rising kidney failure, prevalence rates, in the Asia-Pacific regions should boost the growth of this market.

KEY BENEFITS

• The analysis, made in this report, helps in understanding the strategies adopted by various companies for gaining market share in hormone refractory breast cancer market
• This report provides a comprehensive analysis of factors that drive and restrict the growth of the hormone refractory breast cancer market
• Detailed study of the strategies of key leaders, partnerships, and acquisitions in the Asia Pacific hormone refractory breast cancer market would be informative for professionals in the corporate sector
• Pin-point analysis of geographic segments helps to identify opportunities for growth within the hormone refractory breast cancer market
• An analysis for the market attractiveness has been included for therapeutics, devices, and geographic regions along with a detailed analysis of factors responsible for the rapid growth of the market segments
• Ease of doing business analysis should help in making strategic business decisions

ASIA-PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET KEY SEGMENTS

BY TREATMENT MODALITY

• Hormone receptor-based therapy
• Tumor markers therapy
• Gene expression therapy
• Gene mutation therapy

BY GEOGRAPHY

• China
• Japan
• India
• Australia
• Others

  Asia Pacific Hormone Refractory Breast Cancer Market Report Highlights